EP4103713A4 - Pan-genotypic agents against respiratory viruses and methods of using the same - Google Patents

Pan-genotypic agents against respiratory viruses and methods of using the same

Info

Publication number
EP4103713A4
EP4103713A4 EP21780993.8A EP21780993A EP4103713A4 EP 4103713 A4 EP4103713 A4 EP 4103713A4 EP 21780993 A EP21780993 A EP 21780993A EP 4103713 A4 EP4103713 A4 EP 4103713A4
Authority
EP
European Patent Office
Prior art keywords
genotypic
pan
methods
same
agents against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21780993.8A
Other languages
German (de)
French (fr)
Other versions
EP4103713A1 (en
Inventor
Jeffrey S Glenn
Rachel Hagey Saluti
Edward A Pham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/792,103 external-priority patent/US11339392B2/en
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority claimed from PCT/US2021/018025 external-priority patent/WO2021201996A1/en
Publication of EP4103713A1 publication Critical patent/EP4103713A1/en
Publication of EP4103713A4 publication Critical patent/EP4103713A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
EP21780993.8A 2020-02-14 2021-02-12 Pan-genotypic agents against respiratory viruses and methods of using the same Pending EP4103713A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/792,103 US11339392B2 (en) 2016-03-02 2020-02-14 Pan-genotypic agents against influenza virus and methods of using the same
US202062992659P 2020-03-20 2020-03-20
PCT/US2021/018025 WO2021201996A1 (en) 2020-02-14 2021-02-12 Pan-genotypic agents against respiratory viruses and methods of using the same

Publications (2)

Publication Number Publication Date
EP4103713A1 EP4103713A1 (en) 2022-12-21
EP4103713A4 true EP4103713A4 (en) 2024-03-20

Family

ID=83688484

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21780993.8A Pending EP4103713A4 (en) 2020-02-14 2021-02-12 Pan-genotypic agents against respiratory viruses and methods of using the same

Country Status (4)

Country Link
EP (1) EP4103713A4 (en)
JP (1) JP2023514576A (en)
CN (1) CN115997014A (en)
CA (1) CA3167206A1 (en)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HAGEY RACHEL J. ET AL: "Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2", NATURE MEDICINE, vol. 28, no. 9, 18 August 2022 (2022-08-18), New York, pages 1944 - 1955, XP093126274, ISSN: 1078-8956, Retrieved from the Internet <URL:https://www.nature.com/articles/s41591-022-01908-x> DOI: 10.1038/s41591-022-01908-x *
See also references of WO2021201996A1 *
SIMONE GIANNECCHINI ET AL: "Oligonucleotides derived from the packaging signal at the 5' end of the viral PB2 segment specifically inhibit influenza virus in vitro", ARCHIVES OF VIROLOGY ; OFFICIAL JOURNAL OF THE VIROLOGY DIVISIONOF THE INTERNATIONAL UNION OF MICROBIOLOGICAL SOCIETIES, SPRINGER-VERLAG, VI, vol. 154, no. 5, 16 April 2009 (2009-04-16), pages 821 - 832, XP019722939, ISSN: 1432-8798 *
SIMONE GIANNECCHINI ET AL: "Packaging signals in the 5-ends of influenza virus PA, PB1, and PB2 genes as potential targets to develop nucleic-acid based antiviral molecules", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 92, no. 1, 21 June 2011 (2011-06-21), pages 64 - 72, XP028293110, ISSN: 0166-3542, [retrieved on 20110629], DOI: 10.1016/J.ANTIVIRAL.2011.06.013 *

Also Published As

Publication number Publication date
CN115997014A (en) 2023-04-21
CA3167206A1 (en) 2021-10-07
EP4103713A1 (en) 2022-12-21
JP2023514576A (en) 2023-04-06

Similar Documents

Publication Publication Date Title
SG11202110145SA (en) Antibodies against sars-cov-2 and methods of using the same
IL271025A (en) Multibiotic agents and methods of using the same
IL290677A (en) Brd9 bifunctional degraders and their methods of use
IL281277A (en) Compositions and methods for the treatment of viral infections
IL292173A (en) Small molecule degraders of helios and methods of use
HUE056471T2 (en) Dalargin for use in the treatment of acute respiratory viral infections
IL288310A (en) Cot modulators and methods of use thereof
EP3752166A4 (en) Trialkyne linking agents and methods of use
EP3749403A4 (en) Self-sanitizing respiratory assembly and methods of making and using the same
EP3982994A4 (en) Compositions and methods for the treatment of respiratory syncytial virus
EP4081308A4 (en) Smarca degraders and uses thereof
EP4076444A4 (en) Indazole derivatives and methods of use thereof for the treatment of herpes viruses
IL287966A (en) Auto-injector and related methods of use
IL299245A (en) Lair-1-binding agents and methods of use thereof
IL280655A (en) Particles containing coloring agents and methods of using the same
IL279178A (en) Modified cas9 protein and use thereof
HK1257588A1 (en) Medicine for preventing and treating lung fibrosis and use of the medicine
EP3463469C0 (en) Combination of ledipasvir and sofosbuvir for use in the treatment of hepatitis b virus infections in humans
IL287829A (en) Progranulin modulators and methods of using the same
GB201904299D0 (en) An exhaust gas treatment system and the use thereof for the treatment of an exhaust gas
GB201810197D0 (en) Respiratory therapy devices and assemblies
EP3996786A4 (en) Respiratory assembly and methods of using the same
EP3976149A4 (en) Respiratory assembly and methods of using the same
EP4103713A4 (en) Pan-genotypic agents against respiratory viruses and methods of using the same
EP3804815A4 (en) Face mask and respirator

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220810

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAV Requested validation state of the european patent: fee paid

Extension state: MD

Effective date: 20220908

Extension state: MA

Effective date: 20220908

A4 Supplementary search report drawn up and despatched

Effective date: 20240216

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/16 20060101ALI20240212BHEP

Ipc: C12N 15/11 20060101AFI20240212BHEP